Orion: Phase III Trial With Darolutamide Meets Primary Endpoint In MHSPC

Orion Oyj announced Orion's and Bayer's (BAYZF.PK,BAYRY.PK,BYR.L) phase III ARASENS trial showed an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy compared to docetaxel and androgen deprivation therapy, a standard of care in metastatic hormone-sensitive prostate cancer. The overall incidence of reported adverse events was similar between treatment arms, the company said.

Bayer plans to discuss the data from ARASENS with health authorities worldwide regarding the submission for marketing authorisation in this indication.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT